Livius Pte. Ltd

LIVIUS Pte. Ltd. is a Singapore-based longevity biotechnology company advancing next-generation therapeutics by targeting cellular aging and genomic instability through cell reprogramming and DNA repair biology. Founded on more than 40 years of research led by our CSO, we have established a proprietary platform combining- miRNA-guided cellular reprogramming - DNA damage response/repair pathway engagement observed during reprogramming (cell-based / preclinical studies)- Small-molecule approaches that upregulate endogenous miRNAs, supporting scalable and cost-effective development What we aim to solve Aging is driven by cellular senescence and accumulated genomic damage. We focus on upstream biology to enable root-cause interventions, rather than downstream symptom management. Core Technology - miRNA-based reprogramming designed to reset epigenetic markers associated with aging - Ongoing validation of DNA repair pathway activation in preclinical settings - Complementary small-molecule formats to support stability, manufacturability, and scale Pipeline Strategy LIVIUS operates a dual-track model: Therapeutics (core value driver): Lead programs in dermatology and ophthalmology are progressing through preclinical / IND-enabling work and IND preparation, alongside discovery programs spanning oncology and other age-related biology. Non-medical / Aesthetic applications (proof of concept & revenue): Science-driven skincare and hair/skin formulations, plus cell-quality enhancement additives. Vision Our mission is to extend healthspan, not just lifespan—by delivering interventions that help restore cellular function. Headquarters: Singapore Global presence: Japan, China, USA, UAE